Topamax Tapering Guide
topiramate
Overview
Topiramate is an anticonvulsant used for epilepsy, migraine prevention, and off-label for mood, alcohol use disorder, and weight loss in obese patients. Cognitive side effects ("Dopamax") are common and can be substantial.
25mg, 50mg, 100mg, 200mg tablets; 15mg, 25mg sprinkle capsules
Tablets: 25mg, 50mg, 100mg, 200mg; Sprinkle capsules: 15mg, 25mg; ER capsules (Trokendi XR, Qudexy XR): 25mg-200mg
Category D (cleft lip/palate risk)
Mechanism of Action
Multiple: blocks voltage-gated sodium channels, enhances GABA-A activity, antagonizes AMPA/kainate glutamate receptors, weakly inhibits carbonic anhydrase.
Taper Notes
Slow taper, especially in seizure or migraine patients. Cognitive side effects often resolve quickly after dose reduction.
Hyperbolic Tapering Guidance
Cognitive blunting is dose-dependent and largely reversible — a fact often missed by patients told their cognitive changes were unrelated.
Summary written by TaperCommunity, informed by the Maudsley Deprescribing Guidelines (Horowitz & Taylor) and related literature — see Sources & References below. Not affiliated with or endorsed by the Maudsley.
Withdrawal Timeline
3-7 days
1-2 weeks
2-4 weeks
Cognitive recovery typically within 2-6 weeks of stopping
Common Withdrawal Symptoms
Interactions & Safety
Drug Interactions
- Carbamazepine, phenytoin — decrease topiramate levels
- Valproate — additive hyperammonemia
- Oral contraceptives — efficacy reduced at higher topiramate doses
Contraindications
- Acute angle-closure glaucoma
Toxicity
Cognitive impairment ("word-finding difficulty"), paresthesias, kidney stones (carbonic anhydrase inhibition), metabolic acidosis, anhidrosis with hyperthermia, weight loss, narrow-angle glaucoma (rare, acute).
Pharmacokinetics
ADME Profile
Largely renal (~70% excreted unchanged); minor hepatic metabolism.
~15-41%
Need a clinician who understands tapering?
Browse our map of deprescribing-informed providers worldwide.
Other Drug Profiles
Sources & References
Topamax (topiramate) information on this page is sourced from peer-reviewed research, regulatory bodies, clinical guidelines, and patient-advocacy organizations.
Encyclopedic & chemical databases
Neutral, high-authority entity references.
Regulatory sources
Official prescribing information and safety notices.
Peer-reviewed research
Primary literature cited in this taper guide.
- Goodwin GM, Haddad PM, Ferrier IN, et al. 2016 — Discontinuation of mood stabilizers: practical considerations and review (Journal of Psychopharmacology)
- Geddes JR, Burgess S, Hawton K, et al. 2004 — Discontinuation of lithium augmentation in elderly patients (American Journal of Psychiatry)
- Horowitz MA, Taylor D 2019 — Tapering of SSRI treatment to mitigate withdrawal symptoms (hyperbolic taper) (The Lancet Psychiatry)
Clinical guidelines
Evidence-based deprescribing and prescribing standards.
Deprescribing-specific resources
Clinician-facing references on tapering protocols.
- International Society for Bipolar Disorders (ISBD) — Specialty society guidance for bipolar maintenance pharmacotherapy
- Deprescribing.org — Clinician-facing deprescribing algorithms
Patient-advocacy & lived-experience
Long-running communities documenting withdrawal experience.
- Surviving Antidepressants — mood stabilizer tapering forum — Community archive of mood-stabilizer discontinuation experiences
- Mad in America — mood stabilizer coverage — Independent journalism on lithium, lamotrigine, and valproate
- Inner Compass Initiative — Withdrawal Project — Peer-led psychiatric drug withdrawal resources
- RxISK — adverse drug reaction reporting — Independent database of mood-stabilizer adverse-effect reports
TaperCommunity does not provide medical advice. Always consult a qualified prescriber before adjusting psychiatric medication.